•
Jun 30, 2024

OptimizeRx Q2 2024 Earnings Report

Reported Q2 2024 financial results with revenue increasing year-over-year.

Key Takeaways

OptimizeRx reported Q2 2024 revenue of $18.8 million, a 36% increase year-over-year. Gross profit increased by 50% to $11.7 million, with a gross margin of 62%. The company reiterated its full-year 2024 revenue guidance of at least $100 million and adjusted EBITDA of at least $11 million.

Q2 revenue reached $18.8 million, a 36% increase year-over-year.

Q2 gross profit increased 50% year-over-year to $11.7 million, with a gross margin of 62%.

The company won 8 DAAP deals during Q2.

Full year 2024 revenue is expected to be at least $100 million.

Total Revenue
$18.8M
Previous year: $13.8M
+36.1%
EPS
$0.02
Previous year: -$0.01
-300.0%
Gross Profit
$11.7M
Previous year: $7.83M
+49.5%
Cash and Equivalents
$15M
Previous year: $9.81M
+52.5%
Free Cash Flow
$737K
Previous year: -$2.39M
-130.9%
Total Assets
$173M
Previous year: $121M
+42.5%

OptimizeRx

OptimizeRx

Forward Guidance

For the full year 2024, the Company is reiterating its 2024 guidance and expects revenue to be at least $100 million with an Adjusted EBITDA of at least $11 million.